Jubilant Pharmova Q2 FY27: revenue up 20.5% to ₹2,370 Cr, net profit down 74.1% to ₹31 Cr
Results · 13 Nov 2026 · Jubilant Pharmova (JUBLPHARMA)
| Q2 FY27 | ₹ Cr | YoY |
|---|---|---|
| Revenue | 2,370 | +20.5% |
| Operating profit | 241 | -29.6% |
| Net profit | 31 | -74.1% |
Jubilant Pharmova reported Q2 FY27 revenue of Rs 2,370 crore, up 21% YoY from Rs 1,966 crore, with EBITDA of Rs 255 crore (down 27% from Rs 351 crore) and reported PAT of Rs 31 crore (down 74% from Rs 120 crore).
EBITDA margins fell on unavailable high-margin SPECT radiopharma products and incremental remediation costs at CMO Montreal, while the company raised Rs 800 crore through NCDs for debt refinancing and capex.
Operating margin was 10.1%, down 7.2 pp on a year earlier and down 1.0 pp on the quarter before.
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.